Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07379788

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Sponsor: Rehab Werida

View on ClinicalTrials.gov

Summary

This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).

Official title: Mitral Remodeling Index: A Novel Composite Measure the Effect of ARNI Alone Versus ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

180

Start Date

2025-12-25

Completion Date

2026-03-01

Last Updated

2026-01-30

Healthy Volunteers

Not specified

Conditions

Interventions

DRUG

Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO]

Patients receiving Sacubitril/Valsartan 49 MG-51 MG Oral Tablet without concomitant SGLT2 inhibitor therapy.

DRUG

Empagliflozin10Mg Tab

Combination Therapy Group: Patients receiving Sacubitril/Valsartan 49 MG-51 MG Oral Tablet in combination with an SGLT2 inhibitor (empagliflozin 10 mg daily).

Locations (1)

Madinah Cardiac Center

Madinah, Saudi Arabia